Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib 160mg in EGFR T790M mutant NSCLC
NCT05701384Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05701384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701384.